These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20551139)

  • 1. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133.
    Zhou F; Cui C; Ge Y; Chen H; Li Q; Yang Z; Wu G; Sun S; Chen K; Gu J; Jiang J; Wei Y
    J Biochem; 2010 Sep; 148(3):273-80. PubMed ID: 20551139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
    Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
    Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133: molecule of the moment.
    Mizrak D; Brittan M; Alison M
    J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.
    Mak AB; Blakely KM; Williams RA; Penttilä PA; Shukalyuk AI; Osman KT; Kasimer D; Ketela T; Moffat J
    J Biol Chem; 2011 Nov; 286(47):41046-56. PubMed ID: 21937449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
    Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
    PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth.
    Liu Y; Ren S; Xie L; Cui C; Xing Y; Liu C; Cao B; Yang F; Li Y; Chen X; Wei Y; Lu H; Jiang J
    Oncotarget; 2015 Aug; 6(24):20650-60. PubMed ID: 26029999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
    Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
    Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD133 as a marker for cancer stem cells: progresses and concerns.
    Wu Y; Wu PY
    Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-glycan structures and associated gene expression reflect the characteristic N-glycosylation pattern of human hematopoietic stem and progenitor cells.
    Hemmoranta H; Satomaa T; Blomqvist M; Heiskanen A; Aitio O; Saarinen J; Natunen J; Partanen J; Laine J; Jaatinen T
    Exp Hematol; 2007 Aug; 35(8):1279-92. PubMed ID: 17662891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limits of CD133 as a marker of glioma self-renewing cells.
    Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
    Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?
    Neuzil J; Stantic M; Zobalova R; Chladova J; Wang X; Prochazka L; Dong L; Andera L; Ralph SJ
    Biochem Biophys Res Commun; 2007 Apr; 355(4):855-9. PubMed ID: 17307142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
    Rentala S; Mangamoori LN
    J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
    Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
    J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
    Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 as a target for colon cancer.
    Catalano V; Di Franco S; Iovino F; Dieli F; Stassi G; Todaro M
    Expert Opin Ther Targets; 2012 Mar; 16(3):259-67. PubMed ID: 22385077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD133 in synovial sarcoma.
    Terry J; Nielsen T
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
    Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
    Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.